Teamwork Financial Advisors LLC Has $1.46 Million Holdings in DexCom, Inc. (NASDAQ:DXCM)

Teamwork Financial Advisors LLC boosted its holdings in shares of DexCom, Inc. (NASDAQ:DXCM) by 49.7% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 18,729 shares of the medical device company’s stock after purchasing an additional 6,221 shares during the period. Teamwork Financial Advisors LLC’s holdings in DexCom were worth $1,457,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently bought and sold shares of DXCM. Versant Capital Management Inc bought a new position in DexCom in the 4th quarter valued at $25,000. Riverview Trust Co boosted its holdings in DexCom by 100.4% in the third quarter. Riverview Trust Co now owns 463 shares of the medical device company’s stock valued at $31,000 after acquiring an additional 232 shares during the last quarter. MassMutual Private Wealth & Trust FSB increased its position in DexCom by 46.7% in the fourth quarter. MassMutual Private Wealth & Trust FSB now owns 833 shares of the medical device company’s stock worth $65,000 after purchasing an additional 265 shares during the period. RPg Family Wealth Advisory LLC bought a new stake in DexCom during the 3rd quarter worth about $57,000. Finally, Park Place Capital Corp lifted its position in DexCom by 3,516.7% during the 4th quarter. Park Place Capital Corp now owns 868 shares of the medical device company’s stock valued at $68,000 after purchasing an additional 844 shares during the period. Institutional investors and hedge funds own 97.75% of the company’s stock.

Insider Transactions at DexCom

In related news, EVP Sadie Stern sold 4,259 shares of DexCom stock in a transaction that occurred on Wednesday, November 20th. The shares were sold at an average price of $74.73, for a total transaction of $318,275.07. Following the sale, the executive vice president now directly owns 71,192 shares in the company, valued at $5,320,178.16. This trade represents a 5.64 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Company insiders own 0.30% of the company’s stock.

DexCom Price Performance

DXCM stock opened at $87.09 on Thursday. The company’s 50-day moving average price is $78.70 and its two-hundred day moving average price is $77.37. DexCom, Inc. has a 12 month low of $62.34 and a 12 month high of $142.00. The company has a quick ratio of 2.12, a current ratio of 2.46 and a debt-to-equity ratio of 1.23. The firm has a market cap of $34.02 billion, a P/E ratio of 52.15, a P/E/G ratio of 2.26 and a beta of 1.12.

Analyst Upgrades and Downgrades

DXCM has been the subject of a number of recent research reports. Robert W. Baird raised shares of DexCom from a “neutral” rating to an “outperform” rating and boosted their price target for the stock from $86.00 to $104.00 in a research note on Thursday, January 16th. Baird R W upgraded DexCom from a “hold” rating to a “strong-buy” rating in a research report on Thursday, January 16th. Sanford C. Bernstein upped their price objective on DexCom from $82.00 to $86.00 and gave the company an “outperform” rating in a report on Friday, October 25th. Citigroup raised their target price on DexCom from $85.00 to $91.00 and gave the stock a “buy” rating in a report on Wednesday, December 11th. Finally, Oppenheimer lowered their price target on DexCom from $115.00 to $105.00 and set an “outperform” rating for the company in a research note on Friday, October 25th. Five equities research analysts have rated the stock with a hold rating, twelve have issued a buy rating and two have assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, DexCom has an average rating of “Moderate Buy” and a consensus target price of $99.29.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.